GlassScriptPhysician profile
Er-Kai Gao
NPI 1710064944
$35,574.00
in general payments reported to CMS, 2019-2025
76 companies · $5,888 in 2025
The $5,888 reported for 2025 was more than what 82% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,196 · 2020: $4,282 · 2021: $2,684 · 2022: $4,352 · 2023: $4,371 · 2024: $6,800 · 2025: $5,888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $197 · Travel and Lodging: $48.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,814.51 |
| Education | $196.74 |
| Travel and Lodging | $48.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,115.69 | 2019-2025 | Zilbrysq, Briviact, Fintepla |
| Livanova USA, INC. | $2,941.82 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Sunovion Pharmaceuticals INC. | $2,676.32 | 2019-2020 | |
| Abbvie INC. | $1,942.95 | 2019-2025 | |
| Sk Life Science, INC. | $1,234.79 | 2020-2025 | Xcopri |
| Boston Scientific Corporation | $1,204.97 | 2019-2022 | |
| Neurelis, INC. | $1,149.56 | 2020-2025 | Valtoco |
| Alnylam Pharmaceuticals INC. | $1,135.30 | 2022-2025 | Amvuttra, Onpattro |
| Biogen, INC. | $1,092.55 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Eisai INC. | $1,073.64 | 2019-2025 | |
| Lilly USA, LLC | $1,029.26 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Alexion Pharmaceuticals, INC. | $897.96 | 2019-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $831.17 | 2019-2024 | Xarelto, Ponvory |
| Teva Pharmaceuticals USA, INC. | $763.98 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Neurocrine Biosciences, INC. | $691.10 | 2019-2025 | Ingrezza, Ongentys |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.26 | 2021-2025 | Andexxa, Wainua |
| Kyowa Kirin, INC. | $587.94 | 2019-2025 | Nourianz |
| Mdd US Operations, LLC | $575.64 | 2019-2025 | Gocovri, Gocovri, Qelbree |
| Lundbeck LLC | $541.48 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $494.82 | 2019-2025 | |
| Horizon Therapeutics Plc | $490.22 | 2022-2023 | Uplizna |
| Amneal Pharmaceuticals LLC | $466.90 | 2019-2025 | Crexont, Rytary |
| Argenx US, INC. | $460.31 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $456.65 | 2019-2025 | Nuplazid |
| Amgen INC. | $448.47 | 2019-2025 | Uplizna |
| Tg Therapeutics, INC. | $424.05 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.49 | 2021-2025 | Hyqvia |
| Biohaven Pharmaceutical Holding Company LTD. | $371.04 | 2022 | |
| Ge Healthcare | $357.01 | 2019-2025 | |
| Genzyme Corporation | $355.57 | 2019-2022 | |
| Csl Behring | $337.03 | 2019-2025 | Hizentra |
| Edw Pharma, INC. | $331.13 | 2024 | Tiglutik |
| Genentech USA, INC. | $330.27 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Pfizer INC. | $323.82 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $317.88 | 2023-2025 | Rexulti |
| Grifols USA, LLC | $278.07 | 2019-2025 | Gamunex-C |
| Allergan, INC. | $266.95 | 2020 | |
| Abbott Laboratories | $238.95 | 2020-2024 | Infinity |
| Janssen Biotech, INC. | $234.01 | 2025 | |
| Emd Serono, INC. | $215.24 | 2019-2020 | |
| Medtronic, INC. | $214.47 | 2021-2023 | Reveal Linq, Linq II |
| Portola Pharmaceuticals, LLC | $194.10 | 2019 | |
| Tanabe Pharma America, INC. | $179.33 | 2019-2025 | Radicava |
| Adamas Pharmaceuticals, INC. | $171.67 | 2019 | |
| Jazz Pharmaceuticals INC. | $160.91 | 2022-2023 | Epidiolex |
| Acorda Therapeutics, INC | $146.68 | 2019-2022 | |
| Greenwich Biosciences, INC. | $144.10 | 2019-2021 | |
| Genentech, INC. | $134.93 | 2024 | Ocrevus |
| Banner Life Sciences, LLC | $134.32 | 2022-2023 | |
| Celgene Corporation | $114.77 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $104.59 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $100.88 | 2021-2024 | Firdapse |
| Merz Pharmaceuticals, LLC | $93.87 | 2024-2025 | Xeomin, Inbrija |
| Akcea Therapeutics, INC. | $88.58 | 2019-2020 | |
| Daiichi Sankyo INC. | $73.75 | 2021 | |
| Axsome Therapeutics, INC. | $68.74 | 2025 | Symbravo |
| Vertical Pharmaceuticals, LLC | $67.43 | 2019 | |
| Vanda Pharmaceuticals INC. | $64.77 | 2019-2022 | |
| Aucta Pharmaceuticals, INC. | $62.44 | 2025 | Motpoly Xr |
| Chiesi USA, INC. | $50.04 | 2019-2022 | |
| Insightec,INC | $47.68 | 2024-2025 | Exablate |
| Arbor Pharmaceuticals, INC. | $44.40 | 2019-2020 | |
| Almatica Pharma LLC | $44.40 | 2021-2022 | |
| Springworks Therapeutics, INC. | $34.97 | 2025 | Gomekli |
| Kedrion Biopharma, INC. | $31.77 | 2025 | Gammaked, Kedrab, Koate |
| Noctrix Health, INC. | $27.18 | 2025 | Nidra |
| Ipsen Biopharmaceuticals, INC | $26.51 | 2023 | Dysport |
| Biohaven Pharmaceuticals, INC. | $25.23 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $24.24 | 2023 | Relyvrio |
| Promius Pharma LLC | $23.08 | 2019 | |
| Octapharma USA, INC. | $22.29 | 2024 | Panzyga |
| Novo Nordisk INC | $21.95 | 2023 | Ozempic, Rybelsus |
| Grt US Holding, INC. | $21.43 | 2020 | |
| Avion Pharmaceuticals | $20.79 | 2023 | Dhivy |
| Assertio Therapeutics, INC. | $15.37 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Er-Kai Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.